Roche chooses Veeva Vault PromoMats for digital asset management and content

pharmafile | December 4, 2018 | News story | Manufacturing and Production, Medical Communications Roche, pharma, veeva 

Today, at the 2018 Veeva Commercial & Medical Summit Europe, Roche (SWX:ROG) announced that it would be adopting Veeva Systems (NYSE:VEEV) Vault PromoMats as its global content and digital asset management solution.

This is part of Roche’s plans to reduce time to market when delivering commercial and medical content, and will help the company to better manage the lifecycles of digital assets, reduce expensive duplication of assets, maintain control of its brand image, and remain compliant in a complex regulatory environment.

Commenting on the announcement, John Chinnici, vice president of commercial content at Veeva, said: “Vault PromoMats gives the life sciences industry a single solution to easily create and distribute content with integrated capabilities to manage rich digital assets. We are proud to partner with Roche on this important initiative to speed time to market for its commercial and medical content.”

By implementing Vault PromoMats, Roche will eliminate the need to move, duplicate, and manage content and digital assets across multiple systems. This will deliver improved visibility, control, and compliance across the digital supply chain.

As the first and only application to combine digital asset management with medical, legal, and regulatory review, Veeva Vault PromoMats provides a single solution to streamline content management and distribution. It combines digital asset management with review and distribution capabilities, providing the only solution built for life sciences. Easy review and approval, plus automated content distribution and withdrawal across channels, ensures complete visibility and control of all materials.

More than 200 life sciences companies across 165+ countries rely on Veeva Vault PromoMats for commercial content and digital asset management.

Matt Fellows

Related Content

Pfizer sign

Delayed Pfizer vaccine dose gives 3.5 times more immunity, study shows

The Pfizer-BioNTech COVID-19 vaccine is around three and a half times more effective when dosed …

Amgen flag

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial

AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority …

India report record number of COVID deaths as bodies drift down Ganges

India yesterday reported the country’s highest COVID-19 death total for a single day, with 4,205 …

Latest content